A. B. Online resource 7 Soria G. et al. Submitted to Neoplasia

Slides:

Advertisements

Similar presentations

Clancy-Thompson et al., Supplemental Figure 1 A B C Supplemental Figure 1: Mice were given intravenous B16 injection on day 0. A) After bearing tumors.

Advertisements

Mandal CC et al Supplementary Fig. S1. Increased expression of CSF-1 in human breast cancer cells. (A) The conditioned media from normal human breast epithelial.

Additional File 1 A. p38 (38 kDa) shRNA Control p53 (53 kDa) shRNA p53 B. Untransfected cells Relative cell no. GFP- vector GFP-Ras G12V Fluorescence Additional.

Functional study of the vitamin K cycle in mammalian cells

Induction of apoptosis by CDIP expression.

FAM49B controls T cell activation by regulating cytoskeleton remodeling. FAM49B controls T cell activation by regulating cytoskeleton remodeling. (A) J.FAM49B.

Yeonsue Jang, Sang H. Jeong, Yoon-Hee Park, Hyun C

Cytokine and chemokine expression of flucloxacillin-specific T cell clones (TCC) of patient P1. Cytokine and chemokine expression of flucloxacillin-specific.

Loss of CCR2 Expression and Functional Response to Monocyte Chemotactic Protein (MCP-1) During the Differentiation of Human Monocytes: Role of Secreted.

Human fibroblasts support the expansion of IL-17–producing T cells via up-regulation of IL-23 production by dendritic cells by Christine Schirmer, Claudia.

(A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza) for 4 d. (A) ZR75-1 cells were treated with 1 μM 5-aza-2′-deoxycytidine (5-Aza)

HUWE1 regulates ubiquitination of Shoc2 and RAF-1.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

(A) Schematic representation of the conditional Lats1 locus.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Expression of SYCE2 activates the DSB repair pathway.

Volume 16, Issue 9, Pages (September 2014)

Volume 27, Issue 2, Pages (August 2007)

Volume 120, Issue 3, Pages (February 2005)

Supplementary Information 1

CCL5 is critical for the activity of CAFs and miR-CAFs.

Molecular Therapy Volume 20, (May 2012) DOI: /S (16)

BRCA1 PARsylation is required for normal HRR tuning.

The PbGAPDH G6 fragment interacts with recombinant CD68.

Expression of SYCE2 inhibits the interaction of HP1α with H3K9me3.

Marta Vilalta, Marjan Rafat, Amato J. Giaccia, Edward E. Graves

XIST regulated miR-29c by directly targetting in TMZ-resistant glioma cells XIST regulated miR-29c by directly targetting in TMZ-resistant glioma cells.

Volume 31, Issue 6, Pages (December 2009)

Volume 8, Issue 3, Pages (September 2003)

Inflammatory cytokine secretion from THP-1 cells, luciferase reporter assay of Nod2-mediated NF-κB activation and NLRP3 expression. Inflammatory cytokine.

Impairment of NK Cell Function by NKG2D Modulation in NOD Mice

HDAC11 regulates CCL2 expression by recruiting PU.1.

IFN-γ Represses IL-4 Expression via IRF-1 and IRF-2

Secretion efficiency of recombinant laminin-111, laminin-511, and their EQ mutants. Secretion efficiency of recombinant laminin-111, laminin-511, and their.

Recruitment of PH-Akt-GFP to the leading edge of the cell during chemotaxis. Recruitment of PH-Akt-GFP to the leading edge of the cell during chemotaxis.

The effects of a dominant negative mutant of lamin B1 on lamin distribution in HeLa cells. The effects of a dominant negative mutant of lamin B1 on lamin.

RXRa serves as a carrier for TR3 translocation initiated by 9-cis retinoic acid. RXRa serves as a carrier for TR3 translocation initiated by 9-cis retinoic.

Knockdown of endogenous WT-hTER by a short hairpin RNA (siRNA) directed specifically against the human WT telomerase RNA template. Knockdown of endogenous.

JAK3A572V mutation causes constitutive JAK3 activity and IL-2–independent proliferation of NKTCL cells. JAK3A572V mutation causes constitutive JAK3 activity.

The K86M mutation in ABCG2 results in a non-functional transporter.

The SIM domain of RAD51 is required for HR

ABCG2-K86M shows a markedly reduced surface expression.

Figure 3 Fingolimod inhibits TNF-α secretion by human monocytes Peripheral blood mononuclear cells from healthy donors were briefly exposed to increasing.

Expression of active Rho partially rescues Erk1/2 activation and peripheral FA phenotype in RIAM-knockdown cells. Expression of active Rho partially rescues.

Kinetics of GFP secretion from CHO cells.

Wrch-1 localizes to focal adhesions.

MiR-431-5p directly targets RAF1 and is negatively correlated to RAF1 expression (A) The predicted binding sites of miR-431-5p and RAF1 3′-UTR, and mutant.

FBXL19-AS1 acts as a sponge of miR-431-5p in lung cancer (A) The predicted binding sites of FBXL19-AS1 and miR-431-5p, and the mutant sites in mutant-type.

(A) Relative expression levels of the top most down-regulated genes in LATS2L breast tumors (TCGA-BRCA dataset, see Fig 1) in the panel of breast cancer.

WT MARCH8, but not the CS mutant, specifically ubiquitinates and downregulates TfR. WT MARCH8, but not the CS mutant, specifically ubiquitinates and downregulates.

C/EBPα induces HSD1 expression and is a substrate of USP2–45.

LATS2 augments oxidative phosphorylation.

Figure 2. p62−/−MEF cells enhance the activation of NF-κB induced by TLR4. (A) Wild-type (WT) p62+/+MEF and p62−/−MEF cells were transfected with pBIIx-luc.

M-MDSC:mast cell cross-talk in the regulation of TNFα production.

Figure 4. MicroRNA (miR)-195 and miR-497 directly targets CD274

Volume 23, Issue 2, Pages (August 2005)

PELP1 regulates the expression and activities of MMPs in ER-negative cells. PELP1 regulates the expression and activities of MMPs in ER-negative cells.

L1-expressing cells preferentially migrate into the wound edge.

Specific inhibition of the Fab-HLA-A2/Flu induction of CTL mediated tumor cell lysis by a competing antibody. Specific inhibition of the Fab-HLA-A2/Flu.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Dilution of anti-C6 monoclonal antibody shows the broader linear range of the Multiplex assay in comparison to standard ELISA. Shown is the dilution of.

Tumor and serum levels of murine IL-12.

IGF-II antibodies inhibited IGF-II-induced phosphorylation of IGF-IR and insulin receptor (IR) in the breast cancer MCF-7 cells. IGF-II antibodies inhibited.

Expression of versican promoted breast cancer cell tumor formation and self-renewal in vivo. Expression of versican promoted breast cancer cell tumor formation.

Transcriptional activity and growth of mutant ER in a breast cancer cell line. Transcriptional activity and growth of mutant ER in a breast cancer cell.

Fig. 3. PTEN a target of miR-182-5p

Target-dependent T cell–mediated cytotoxicity of HER2-TDB.

Transfection efficiency and PicoGreen cell survival assays.

In the presence of human monocytes, estradiol increased breast cancer cell dissemination to the periphery via CCL2 and CCL5. In the presence of human monocytes,

Fig. 3 Three small molecules inhibit the transport of CCR5 and do not affect transport of CCR1 or CXCR4. Three small molecules inhibit the transport of.

Presentation transcript:

A. B. Online resource 7 Soria G. et al. Submitted to Neoplasia Title of manuscript: The secretion of the chemokine CCL5 by breast tumor cells is regulated by the 40s loop of the chemokine and by intracellular glycosaminoglycans A. B. p=0.04 p=0.02 Relative detection of GFP-CCL5 release (%) CCL5 Extracellular Expression (pg/107 cells) GFP-CCL5 (WT) GFP-CCL5 (TRKN--) GFP-CCL5 (WT) GFP-CCL5 (TRKN--) Further evidence to prominent reduction in secretion of GFP-CCL5(TRKN--) compared to GFP-CCL5(WT) by breast tumor cells Human MCF-7 breast tumor cells were transiently transfected by vectors expressing GFP-CCL5(WT) or GFP-CCL5(TRKN--), followed by determination of chemokine expression in cell supernatants. (A) ELISA assays with mAb to GFP and polyclonal detecting antibodies to CCL5 (“Procedure 3” in “Materials and methods”). (B) ELISA assays with polyclonal coating antibodies to CCL5 and polyclonal detecting antibodies to CCL5 (“Procedure 4” in “Materials and methods”).